Literature DB >> 15212966

Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2gamma2L GABAA receptors.

Shelley H Huang1, Rujee K Duke, Mary Chebib, Keiko Sasaki, Keiji Wada, Graham A R Johnston.   

Abstract

Ginkgolides A, B, and C are diterpene trilactones and active constituents of the 50:1 Ginkgo biloba leaf extract widely used in the symptomatic treatment of mild to moderate dementia. Using the two-electrode voltage clamp methodology, these ginkgolides were found to be moderately potent antagonists at recombinant human alpha(1)beta(2)gamma(2L) GABA(A) receptors expressed in Xenopus oocytes. Ginkgolides A, B, and C inhibited the direct action of gamma-aminobutyric acid (GABA) with K(i) values of 14.5+/-1.0, 12.7+/-1.7, and 16.3+/-2.4 microM respectively. Antagonism by these ginkgolides at alpha(1)beta(2)gamma(2L) GABA(A) receptors appears to be noncompetitive as indicated by the nonparallel right shift and reduced maximal GABA response in their GABA concentration-effect curves.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212966     DOI: 10.1016/j.ejphar.2004.04.051

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Complementary and alternative medicine: is there a role in multiple sclerosis?

Authors:  Vijayshree Yadav; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor.

Authors:  A J Thompson; R K Duke; S C R Lummis
Journal:  Mol Pharmacol       Date:  2011-04-19       Impact factor: 4.436

3.  How similar is similar enough? A sufficient similarity case study with Ginkgo biloba extract.

Authors:  Natasha R Catlin; Bradley J Collins; Scott S Auerbach; Stephen S Ferguson; James M Harnly; Chris Gennings; Suramya Waidyanatha; Glenn E Rice; Stephanie L Smith-Roe; Kristine L Witt; Cynthia V Rider
Journal:  Food Chem Toxicol       Date:  2018-05-09       Impact factor: 6.023

4.  Toxicity and carcinogenicity studies of Ginkgo biloba extract in rat and mouse: liver, thyroid, and nose are targets.

Authors:  Cynthia V Rider; Abraham Nyska; Michelle C Cora; Grace E Kissling; Cynthia Smith; Gregory S Travlos; Milton R Hejtmancik; Laurene M Fomby; Curtis A Colleton; Michael J Ryan; Linda Kooistra; James P Morrison; Po C Chan
Journal:  Toxicol Pathol       Date:  2013-08-19       Impact factor: 1.902

5.  Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models.

Authors:  Hong Zhou; Jinsheng Gao; Li Zhou; Xin Li; Weidong Li; Xuejun Li; Yin Xia; Baoxue Yang
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

Review 6.  Therapy for acute pancreatitis with platelet-activating factor receptor antagonists.

Authors:  Chong Chen; Shi-Hai Xia; Hong Chen; Xiao-Hong Li
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

7.  The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex.

Authors:  T Yoshitake; S Yoshitake; J Kehr
Journal:  Br J Pharmacol       Date:  2010-01-25       Impact factor: 8.739

8.  Ginkgolide X is a potent antagonist of anionic Cys-loop receptors with a unique selectivity profile at glycine receptors.

Authors:  Anders A Jensen; Marianne L Bergmann; Tommy Sander; Thomas Balle
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

9.  Mixed antagonistic effects of the ginkgolides at recombinant human ρ1 GABAC receptors.

Authors:  Shelley H Huang; Trevor M Lewis; Sarah C R Lummis; Andrew J Thompson; Mary Chebib; Graham A R Johnston; Rujee K Duke
Journal:  Neuropharmacology       Date:  2012-07-22       Impact factor: 5.250

10.  Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site.

Authors:  Andrew J Thompson; Gavin E Jarvis; Rujee K Duke; Graham A R Johnston; Sarah C R Lummis
Journal:  Neuropharmacology       Date:  2010-11-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.